Search

Your search keyword '"Horváth, Iván"' showing total 249 results
Start Over Author "Horváth, Iván"
249 results on '"Horváth, Iván"'

101. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, primary, Valgimigli, Marco, additional, Jüni, Peter, additional, Hamm, Christian, additional, Steg, Philippe Gabriel, additional, Heg, Dik, additional, van Es, Gerrit Anne, additional, McFadden, Eugene P, additional, Onuma, Yoshinobu, additional, van Meijeren, Cokky, additional, Chichareon, Ply, additional, Benit, Edouard, additional, Möllmann, Helge, additional, Janssens, Luc, additional, Ferrario, Maurizio, additional, Moschovitis, Aris, additional, Zurakowski, Aleksander, additional, Dominici, Marcello, additional, Van Geuns, Robert Jan, additional, Huber, Kurt, additional, Slagboom, Ton, additional, Serruys, Patrick W, additional, Windecker, Stephan, additional, Abdellaoui, Mohamed, additional, Adlam, David, additional, Akin, Ibrahim, additional, Albarran Gonzalez-Trevilla, Agustin, additional, Almeida, Manuel, additional, Alves Lemos Neto, Pedro, additional, Aminian, Adel, additional, Anderson, Richard, additional, Andreae, Rick, additional, Angioi, Michael, additional, Asano, Taku, additional, Barbato, Emanuele, additional, Barlis, Peter, additional, Barraud, Pascal, additional, Bertrand, Olivier, additional, Beygui, Farzin, additional, Bolognese, Leonardo, additional, Botelho, Roberto, additional, Bouwman, Coby, additional, Bressers, Marco, additional, Brunel, Philippe, additional, Buszman, Pawel, additional, Buysschaert, Ian, additional, Canas da Silva, Pedro, additional, Carrie, Didier, additional, Cequier, Angel, additional, Chin Chang, Chun, additional, Chowdhary, Saqib, additional, Collet, Carlos, additional, Colombo, Antonio, additional, Cotton, James, additional, Cruz Ferreira, Rui, additional, Curello, Salvatore, additional, Curzen, Nick, additional, de Bot, Judith, additional, de Vreede, Tone, additional, Delle Karth, Georg, additional, Dijksma, Lynn, additional, Édes, István, additional, Eeckhout, Eric, additional, Eitel, Ingo, additional, Faluközy, József, additional, Fath-Ordoubadi, Farzin, additional, Fontos, Geza, additional, Francisco Diaz, Jose, additional, Freitas Quintella, Edgard, additional, Frey, Bernhard, additional, Friedrich, Guy, additional, Galasko, Gavin, additional, Galuszka, Grzegorz, additional, Gama Ribeiro, Vasco, additional, Garg, Scot, additional, Gargiulo, Giuseppe, additional, Geisler, Tobias, additional, Gelev, Valeri, additional, Ghandilyan, Art, additional, Goicolea, Javier, additional, Gori, Tommaso, additional, Gragnano, Felice, additional, Guimarães, Ana, additional, Haude, Michael, additional, Heijke, Pieter, additional, Hernández Antolin, Rosa Ana, additional, Hildick-Smith, David, additional, Hillen, Dorien, additional, Hoekman, Ina, additional, Hofma, Sjoerd, additional, Holmvang, Lene, additional, Hoole, Stephen, additional, Horváth, Iván, additional, Hugense, Annemarie, additional, Ibrahim, Karim, additional, Iñiguez, Andres, additional, Isaaz, Karl, additional, Jambrik, Zoltán, additional, Jasionowicz, Pawel, additional, Jonk, Judith, additional, Jung, Werner, additional, Katagiri, Yuki, additional, Kogame, Norihiro, additional, Koh, Tian Hai, additional, Koning, René, additional, Konteva, Mariana, additional, Kőszegi, Zsolt, additional, Krackhardt, Florian, additional, Kreuger, Yvonne, additional, Kukreja, Neville, additional, Ladan, Boudijn, additional, Lantelme, Pierre, additional, Leandro, Sergio, additional, Leibundgut, Gregor, additional, Liebetrau, Christoph, additional, Lindeboom, Wietze, additional, Macaya Miguel, Carlos, additional, Mach, François, additional, Magro, Michael, additional, Maillard, Luc, additional, Manavifar, Negar, additional, Mauri, Laura, additional, McFadden, Eugene, additional, Merkely, Bela, additional, Miyazaki, Yosuke, additional, Młodziankowski, Adam, additional, Moccetti, Tiziano, additional, Modolo, Rodrigo, additional, Möllman, Helge, additional, Morelle, Jean-François, additional, Munndt Ottesen, Michael, additional, Muurling, Martin, additional, Naber, Christoph Kurt, additional, Neumann, Franz-Josef, additional, Oldroyd, Keith, additional, Ong, Paul, additional, Palsrok, Sanne, additional, Petrov, Ivo, additional, Plante, Sylvain, additional, Prokopczuk, Janusz, additional, Rademaker-Havinga, Tessa, additional, Raffel, Christopher, additional, Rensing, Benno, additional, Roffi, Marco, additional, Royaards, Kees-Jan, additional, Sabate, Manel, additional, Schächinger, Volker, additional, Seidler, Tim, additional, Serra Peñaranda, Antonio, additional, Serruys, Patrick, additional, Sikarulidze, Lali, additional, Soliman, Osama I, additional, Sousa, Amanda, additional, Spitzer, Ernest, additional, Stables, Rod, additional, Steg, Gabriel, additional, Steinwender, Clemens, additional, Subkovas, Eduardas, additional, Suryapranata, Harry, additional, Takahashi, Kuniaki, additional, Talwar, Suneel, additional, Teiger, Emmanuel, additional, ter Weele, Addy, additional, Teurlings, Eva, additional, Thury, Attila, additional, Tijssen, Jan, additional, Tonev, Gincho, additional, Trendafilova-Lazarova, Diana, additional, Tumscitz, Carlo, additional, Umans, Victor, additional, Ungi, Imre, additional, Valkov, Veselin, additional, van der Harst, Pim, additional, van Geuns, Robert Jan, additional, Vassilev, Dobrin, additional, Velchev, Vasil, additional, Velthuizen, Esther, additional, Verheugt, Freek, additional, Vlcek, Natalia, additional, vom Dahl, Jürgen, additional, Vrolix, Mathias, additional, Walsh, Simon, additional, Werner, Nikos, additional, Witsenburg, Maarten, additional, Zaman, Azfar, additional, Żmudka, Krzysztof, additional, Zrenner, Bernhard, additional, and Zweiker, Robert, additional

Published
2018
Full Text
View/download PDF

108. Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction

Author

Montalescot, Gilles, primary, van ’t Hof, Arnoud W., additional, Bolognese, Leonardo, additional, Cantor, Warren J., additional, Cequier, Angel, additional, Chettibi, Mohamed, additional, Collet, Jean-Philippe, additional, Goodman, Shaun G., additional, Hammett, Christopher J., additional, Huber, Kurt, additional, Janzon, Magnus, additional, Lapostolle, Frédéric, additional, Lassen, Jens Flensted, additional, Licour, Muriel, additional, Merkely, Béla, additional, Salhi, Néjoua, additional, Silvain, Johanne, additional, Storey, Robert F., additional, ten Berg, Jurriën M., additional, Tsatsaris, Anne, additional, Zeymer, Uwe, additional, Vicaut, Eric, additional, Hamm, Christian W., additional, Bougherbal, Rachid, additional, Bouafia, Mohamed Tahar, additional, Nibouche, Djamaleddine, additional, Moklati, Abdelkader, additional, Benalia, Ahmed, additional, Kaid, Omar, additional, Krim, Messaad, additional, Hammett, Christopher, additional, Garrahy, Paul, additional, Jayasinghe, Rohan, additional, Rashford, Stephen, additional, Neunteufl, Thomas, additional, Brussee, Helmut, additional, Alber, Hannes, additional, Weidinger, Franz, additional, Brunner, Michael, additional, Sipoetz, Johann, additional, Prause, Gerhard, additional, Baubin, Michael, additional, Sebald, Dieter, additional, Cantor, Warren, additional, Vijayaraghavan, Ram, additional, Bata, Iqbal, additional, Lavoie, Andrea, additional, Ravkilde, Jan, additional, Jensen, Lisette Okkels, additional, Christensen, Alf Møl, additional, Toftegaard, Marianne, additional, Köhler, Dennis, additional, Montalescot, Gilles, additional, Ducrocq, Gregory, additional, Danchin, Nicolas, additional, Henry, Patrick, additional, Livarek, Bernard, additional, Berthier, Romain, additional, Hovasse, Thomas, additional, Garot, Philippe, additional, Payot, Laurent, additional, Benamer, Hakim, additional, Esteve, Jean Baptiste, additional, Elhadad, Simon, additional, Teiger, Emmanuel, additional, Bonnet, Jean Louis, additional, Paganelli, Franck, additional, Cottin, Yves, additional, Schiele, François, additional, Thuaire, Christophe, additional, Cayla, Guillaume, additional, Coste, Pierre, additional, Ohlmann, Patrick, additional, Cudraz, Eric Bonnefoy, additional, Lantelme, Pierre, additional, Perret, Thibault, additional, Tron, Christophe, additional, De Labriolle, Axel, additional, Aptecar, Edouardo, additional, Beliard, Olivier, additional, Varenne, Olivier, additional, El Mahmoud, Rami, additional, Filippi-Codaccioni, Emmanuelle, additional, Angoulvant, Denis, additional, Peycher, Patrick, additional, Poitrineau, Olivier, additional, Tabone, Xavier, additional, Ecollan, Patrick, additional, Broche, Claire, additional, Lambert, Yves, additional, Briole, Nicolas, additional, Beruben, Arielle, additional, Porcher, Nicolas, additional, Auffray, Jean-Pierre, additional, Freysz, Marc, additional, Depardieu, Franck, additional, Poubel, David, additional, De La Cousaye, Jean-Emmanuel, additional, Bartier, Jean-Claude, additional, Jardel, Benoît, additional, Boulanger, Bertrand, additional, Labourel, Hervé, additional, Soulat, Louis-Christophe, additional, Julie, Véronique, additional, Thicoipe, Michel, additional, Capel, Olivier, additional, Stibbe, Olivier, additional, Carli, Pierre, additional, Tazarourte, Karim, additional, Alcouffe, Fabrice, additional, Aboucaya, David, additional, Aubert, Gaële, additional, Kierzek, Gérald, additional, Cahun-Giraud, Séverine, additional, Hamm, Christian, additional, Dengler, Thomas, additional, Prondzinsky, Roland, additional, Biever, Paul Marc, additional, Schäfer, Andreas, additional, Seyfarth, Melchior, additional, Lemke, Bernd, additional, Werner, Gerald, additional, Nef, Holger, additional, Steiger, Holger, additional, Leschke, Matthias, additional, Münzel, Thomas, additional, Dell Orto, Marco Campo, additional, Loges, Christian, additional, Schinke, Monika, additional, Koberne, Frank, additional, Reiffen, Hans Peter, additional, Tiroch, Klaus, additional, Wierich, Dirk, additional, Kneussel, Michael, additional, Little, Simon, additional, Sauer, Hartmut, additional, Laufenberg-Feldmann, Rita, additional, Ungi, Imre, additional, Horváth, Iván, additional, Édes, István, additional, Mártai, István, additional, Berti, Sergio, additional, Chiarella, Francesco, additional, Calabria, Paolo, additional, Fineschi, Massimo, additional, Galvani, Marcello, additional, Valgimigli, Marco, additional, Moretti, Luciano, additional, Tespili, Maurizio, additional, Mandó, Massimo, additional, Bermano, Francesco, additional, Biagioni, Robusto, additional, Fabbri, Andrea, additional, Ricciardelli, Adelina, additional, Petroni, Maria Romana, additional, Vatteroni, Umberto Roberto, additional, Palumbo, Francesco, additional, Willems, Frank F., additional, Al Mafragi, Amar, additional, Heestermans, Ton A.A.C.M., additional, Van Eck, Martijn J., additional, Heutz, Wim M.J.M., additional, Meppelder, H.H., additional, Jong, Anika Roukema-de, additional, Van de Pas, Harm, additional, Fillat, Ángel Cequier, additional, Tenas, Manel Sabaté, additional, Ferrer, Josepa Mauri, additional, Peñaranda, Antoni Serra, additional, Ferrer, Joan Ángel, additional, Del Blanco, Bruno García, additional, Guardiola, Faustino Miranda, additional, Ruiz Nodar, Juan Miguel, additional, Romo, Andrés Íñiguez, additional, González, Nicolás Vázquez, additional, Nouche, Ramiro Trillo, additional, De La Llera, Luis Díaz, additional, Hernández García, José María, additional, Rivero-Crespo, Fernando, additional, Hernández, Felipe Hernández, additional, Zamorano Gómez, José Luis, additional, Fárega, Xavier Jiménez, additional, Fernández, Gilberto Alonso, additional, Toboso, José Luis, additional, Carrasco, Mercedes, additional, Barreiro, Victoria, additional, Iglesias Vázquez, José Antonio, additional, Montero, María del Mar Ruiz, additional, Ortiz, Fernando Rosell, additional, Escudero, Guillermo Garcia, additional, Ingelmo, Vicente Sánchez-Brunete, additional, García, Antonio Lara, additional, Oldgren, Jonas, additional, Calais, Fredrik, additional, Kastberg, Robert, additional, Bergsten, Per-Adolf, additional, Blomberg, Hans, additional, Thörn, Kristian, additional, Skoog, Gunnar, additional, Zaman, Azfar, additional, Gerber, Robert, additional, Ryding, Alisdair, additional, Spence, Mark, additional, Swanson, Neil, additional, Been, Martin, additional, Grosser, Konrad, additional, Schofield, Peter, additional, Mackin, David, additional, Fell, Paul, additional, Quinn, Tom, additional, Foster, Teresa, additional, McManus, David, additional, and Carson, Andy, additional

Published
2016
Full Text
View/download PDF

110. A Nikolsburgi ábécé hitelességének kérdése: előzetes közlemény

Author

Horváth, Iván, Harangozó, Ádám, Németh, Nikolett, Tubay, Tiziano, Régi Magyar Irodalom Tanszék, Irodalomtudományi Intézet, Irodalomtudományi Doktori Iskola, and MTA-ELTE Hálózati Kritikai Szövegkiadás Kutatócsoport (2006-ig: MTA-ELTE Ideológia Kutatócsoport)

Published
2011

112. One-year outcomes in unselected patients treated with a thin-strut, platinum-chromium, paclitaxel-eluting stent: primary endpoint results from the TAXUS Element European post-approval surveillance study (TE-PROVE)

Author

Tamburino, Corrado, primary, Capodanno, Davide, additional, Erglis, Andrejs, additional, Menown, Ian B.A., additional, Horváth, Iván G., additional, Moreno, Raul, additional, Gilbert, Timothy J., additional, Crowley, James J., additional, Calabria, Paolo, additional, Allocco, Dominic J., additional, and Dawkins, Keith D., additional

Published
2015
Full Text
View/download PDF

115. Towards a Typology of Poetic Forms. From Language to Metrics and Beyond

Author

Aroui, Jean-Louis, Hayes, Bruce, Dell, François, Halle, John, Noel Aziz Hanna, Patrizia, Vetterle, Robert, Dufter, Andreas, De Cornulier, Benoît, Blondel, Marion, Miller, Christopher, Fabb, Nigel, Halle, Morris, Paoli, Bruno, Minkova, Donka, Friedberg, Nila, Dominicy, Marc, Nasta, Mihai, Hanson, Kristin, Piera, Carlos, Arleo, Andy, Floquet, Oreste, Billy, Dominique, Domínguez Caparrós, José, Horváth, Iván, Structures Formelles du Langage (SFL), Université Paris Lumières (UPL)-Centre National de la Recherche Scientifique (CNRS)-Université Paris 8 Vincennes-Saint-Denis (UP8), Groupe de recherche sur la surdité et la LSQ, Université du Québec à Montréal = University of Québec in Montréal (UQAM), Institut Français du Proche-Orient (IFPO), MIN AFF ETRANG-Centre National de la Recherche Scientifique (CNRS), Centre de recherche sur les identités, les nations et l'interculturalité (CRINI), Université de Nantes - UFR Faculté des Langues et Cultures Etrangères (UFR FLCE), Université de Nantes (UN)-Université de Nantes (UN), Modèles, Dynamiques, Corpus (MoDyCo), Université Paris Nanterre (UPN)-Centre National de la Recherche Scientifique (CNRS), and Université Paris 8 Vincennes-Saint-Denis (UP8)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Lumières (UPL)

Subjects
Zwiefache, greek metrics, versification, line ending, translation, generative metrics, caesura, English metrics, nursery rhyme, metrics, verse, spanish metrics, Hungarian metrics, italian metrics, rhyme, song, French metrics, stanza, metrical typology, sung metrics, sign languages, Tristan Corbière, arabic metrics, Joseph Brodsky, elision, alliterative verse, musical textsetting, ablaut reduplication, W.H. Auden, chant, [SCCO.LING]Cognitive science/Linguistics, sonnet, middle English, Sephardic song
Abstract

Metrics is often defined as a discipline that concerns itself with the study of meters. In this volume the term is used in a broader sense that more or less coincides with the traditional notion of "versification". Understood this way, metrics is an eminently complex object that displays variation over time and in space, that concerns forms of a great variety and with different statuses (meters, rhymes, stanzas, prescribed forms, syllabification rules, nursery rhymes, slogans, musical textsetting, ablaut reduplication etc.), and that as a cultural manifestation is performed in a variety of ways (sung, chanted, spoken, read) that can have direct consequences on how it is structured. This profusion of forms is thought to correspond, at the level of perception, to a limited number of cognitive mechanisms that allow us to perceive and to represent regularly iterating forms. This volume proposes a relatively coherent overall vision by distinguishing four main families of metrical forms, each clearly independent of the others and amenable to separate typologies.

Published
2009

118. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vsaspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

Author

Vranckx, Pascal, Valgimigli, Marco, Jüni, Peter, Hamm, Christian, Steg, Philippe Gabriel, Heg, Dik, van Es, Gerrit Anne, McFadden, Eugene P, Onuma, Yoshinobu, van Meijeren, Cokky, Chichareon, Ply, Benit, Edouard, Möllmann, Helge, Janssens, Luc, Ferrario, Maurizio, Moschovitis, Aris, Zurakowski, Aleksander, Dominici, Marcello, Van Geuns, Robert Jan, Huber, Kurt, Slagboom, Ton, Serruys, Patrick W, Windecker, Stephan, Abdellaoui, Mohamed, Adlam, David, Akin, Ibrahim, Albarran Gonzalez-Trevilla, Agustin, Almeida, Manuel, Alves Lemos Neto, Pedro, Aminian, Adel, Anderson, Richard, Andreae, Rick, Angioi, Michael, Asano, Taku, Barbato, Emanuele, Barlis, Peter, Barraud, Pascal, Benit, Edouard, Bertrand, Olivier, Beygui, Farzin, Bolognese, Leonardo, Botelho, Roberto, Bouwman, Coby, Bressers, Marco, Brunel, Philippe, Buszman, Pawel, Buysschaert, Ian, Canas da Silva, Pedro, Carrie, Didier, Cequier, Angel, Chichareon, Ply, Chin Chang, Chun, Chowdhary, Saqib, Collet, Carlos, Colombo, Antonio, Cotton, James, Cruz Ferreira, Rui, Curello, Salvatore, Curzen, Nick, de Bot, Judith, de Vreede, Tone, Delle Karth, Georg, Dijksma, Lynn, Dominici, Marcello, Édes, István, Eeckhout, Eric, Eitel, Ingo, Faluközy, József, Fath-Ordoubadi, Farzin, Ferrario, Maurizio, Fontos, Geza, Francisco Diaz, Jose, Freitas Quintella, Edgard, Frey, Bernhard, Friedrich, Guy, Galasko, Gavin, Galuszka, Grzegorz, Gama Ribeiro, Vasco, Garg, Scot, Gargiulo, Giuseppe, Geisler, Tobias, Gelev, Valeri, Ghandilyan, Art, Goicolea, Javier, Gori, Tommaso, Gragnano, Felice, Guimarães, Ana, Hamm, Christian, Haude, Michael, Heg, Dik, Heijke, Pieter, Hernández Antolin, Rosa Ana, Hildick-Smith, David, Hillen, Dorien, Hoekman, Ina, Hofma, Sjoerd, Holmvang, Lene, Hoole, Stephen, Horváth, Iván, Huber, Kurt, Hugense, Annemarie, Ibrahim, Karim, Iñiguez, Andres, Isaaz, Karl, Jambrik, Zoltán, Janssens, Luc, Jasionowicz, Pawel, Jonk, Judith, Jung, Werner, Jüni, Peter, Katagiri, Yuki, Kogame, Norihiro, Koh, Tian Hai, Koning, René, Konteva, Mariana, Kőszegi, Zsolt, Krackhardt, Florian, Kreuger, Yvonne, Kukreja, Neville, Ladan, Boudijn, Lantelme, Pierre, Leandro, Sergio, Leibundgut, Gregor, Liebetrau, Christoph, Lindeboom, Wietze, Macaya Miguel, Carlos, Mach, François, Magro, Michael, Maillard, Luc, Manavifar, Negar, Mauri, Laura, McFadden, Eugene, Merkely, Bela, Miyazaki, Yosuke, Młodziankowski, Adam, Moccetti, Tiziano, Modolo, Rodrigo, Möllman, Helge, Morelle, Jean-François, Moschovitis, Aris, Munndt Ottesen, Michael, Muurling, Martin, Naber, Christoph Kurt, Neumann, Franz-Josef, Oldroyd, Keith, Ong, Paul, Onuma, Yoshinobu, Palsrok, Sanne, Petrov, Ivo, Plante, Sylvain, Prokopczuk, Janusz, Rademaker-Havinga, Tessa, Raffel, Christopher, Rensing, Benno, Roffi, Marco, Royaards, Kees-Jan, Sabate, Manel, Schächinger, Volker, Seidler, Tim, Serra Peñaranda, Antonio, Serruys, Patrick, Sikarulidze, Lali, Slagboom, Ton, Soliman, Osama I, Sousa, Amanda, Spitzer, Ernest, Stables, Rod, Steg, Gabriel, Steinwender, Clemens, Subkovas, Eduardas, Suryapranata, Harry, Takahashi, Kuniaki, Talwar, Suneel, Teiger, Emmanuel, ter Weele, Addy, Teurlings, Eva, Thury, Attila, Tijssen, Jan, Tonev, Gincho, Trendafilova-Lazarova, Diana, Tumscitz, Carlo, Umans, Victor, Ungi, Imre, Valkov, Veselin, van der Harst, Pim, van Geuns, Robert Jan, van Meijeren, Cokky, Vassilev, Dobrin, Velchev, Vasil, Velthuizen, Esther, Verheugt, Freek, Vlcek, Natalia, vom Dahl, Jürgen, Vrolix, Mathias, Walsh, Simon, Werner, Nikos, Windecker, Stephan, Witsenburg, Maarten, Zaman, Azfar, Żmudka, Krzysztof, Zrenner, Bernhard, Zurakowski, Aleksander, and Zweiker, Robert

Abstract

We hypothesised that ticagrelor, in combination with aspirin for 1 month, followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.

Published
2018
Full Text
View/download PDF

119. TCT-178 Primary Endpoint Results from the TAXUS Element Post-Approval Surveillance Study (TE-PROVE): 1-Year Outcomes in Unselected Patients Treated With a Thin-Strut, Platinum-Chromium, Paclitaxel-Eluting Stent

Author

Tamburino, Corrado, primary, Erglis, Andrejs, additional, Menown, Ian, additional, Horváth, Iván G., additional, Lecoq, Guillame, additional, Moreno, Raul, additional, Gilbert, Timothy J., additional, Capodanno, Davide, additional, Allocco, Dominic J., additional, and Dawkins, Keith D., additional

Published
2013
Full Text
View/download PDF

131. Prolactin-releasing peptide regulates cardiac contractility

Author

Kónyi, Attila, primary, Skoumal, Réka, additional, Kubin, Anna-Maria, additional, Füredi, Gábor, additional, Perjés, Ábel, additional, Farkasfalvi, Klára, additional, Sárszegi, Zsolt, additional, Horkay, Ferenc, additional, Horváth, Iván G., additional, Tóth, Miklós, additional, Ruskoaho, Heikki, additional, and Szokodi, István, additional

Published
2010
Full Text
View/download PDF

134. Functionally Opposing Roles of Extracellular Signal-Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase in the Regulation of Cardiac Contractility

Author

Szokodi, István, primary, Kerkelä, Risto, additional, Kubin, Anna-Maria, additional, Sármán, Balázs, additional, Pikkarainen, Sampsa, additional, Kónyi, Attila, additional, Horváth, Iván G., additional, Papp, Lajos, additional, Tóth, Miklós, additional, Skoumal, Réka, additional, and Ruskoaho, Heikki, additional

Published
2008
Full Text
View/download PDF

140. Low platelet disaggregation predicts poor response to 150 mg clopidogrel in patients with elevated platelet reactivity.

Author

Aradi, Dániel, Vorobcsuk, András, Lenkey, Zsófia, Horváth, Iván Gábor, and Komócsi, András

Subjects
CORONARY disease, PLATELET aggregation inhibitors, CLOPIDOGREL, REGRESSION analysis, ANGIOPLASTY, BLOOD platelets, PATIENTS
Abstract

Raising the maintenance dose of clopidogrel to 150 mg enhances platelet inhibition (PI) in patients with elevated platelet reactivity (EPR); however, large differences were observed between individuals in the extent of this benefit. We aimed to find clinical and platelet function variables that might predict the response to 150 mg clopidogrel in patients with EPR. ADP 5 µM-stimulated peak aggregation (Aggmax), 6-minute late aggregation (Agglate) and 6-minute disaggregation (disAgg) were measured with light transmission aggregometry (LTA) in a consecutive cohort of 202 patients admitted for emergent or elective percutaneous coronary intervention (PCI) after receiving a 600-mg loading dose of clopidogrel. PI was assessed 12 to 18 hours after loading dose and 30 days after the intervention. EPR was defined as a Aggmax value greater than 34%. From the first day of PCI, 85 patients with EPR received 150 mg clopidogrel for 30 days, while others with normal platelet reactivity (NPR) took 75 mg clopidogrel. Baseline clinical and LTA variables were analyzed in multivariable regression models. Administration of 150 mg clopidogrel enhanced PI and decreased the prevalence of EPR at 30 days compared to the peri-interventional period (Aggmax: 46.9 ± 8.3 vs. 37.3 ± 11.5; EPR: 100% vs. 62.4%; p < 0.001 in both cases); however, the achieved level of platelet reactivity was higher than patients with NPR (Aggmax: 20.6 ± 8.1 vs. 25.3 ± 10.8, p < 0.001). Multivariable logistic regression revealed low platelet disaggregation (odds ratio (OR): 12.49; 95% CI: 2.52–62.00; P = 0.002) and acute coronary syndrome (OR: 4.83; 95% CI: 1.54–15.09; P = 0.008) as independent predictors of EPR. The area under the receiver-operating-characteristic curve was 0.72 ± 0.06 for disaggregation to predict NPR after 150 mg clopidogrel. The optimal disaggregation cut-off was 16.5% with a sensitivity of 94% and a specificity of 43%. Administering 150 mg maintenance dose of clopidogrel enhanced antiplatelet potency; however, more than half of the patients persisted with EPR. Acute coronary syndrome and low (<16.5%) platelet disaggregation are independent predictors of poor benefit from dose shift. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

141. Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing Impact of Prasugrel and High-Dose Clopidogrel

Author

Aradi, Dániel, Tornyos, Adrienn, Pintér, Tünde, Vorobcsuk, András, Kónyi, Attila, Faluközy, József, Veress, Gábor, Magyari, Balázs, Horváth, Iván G., and Komócsi, András

Subjects
stent thrombosis, high-dose clopidogrel, high platelet reactivity, PCI, cardiovascular diseases, bleeding, mortality, platelet function testing, prasugrel
Abstract

ObjectivesThis study sought to evaluate the impact of treatment with prasugrel and high-dose clopidogrel on the basis of platelet function testing in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI).BackgroundThe clinical impact of treatment with prasugrel in patients with ACS who have high platelet reactivity (HPR) is unknown.MethodsPatients with ACS who were pre-treated with clopidogrel and undergoing successful PCI were enrolled in a single-center, prospective registry. Platelet function was measured 12 to 36 h after PCI with the Multiplate device (Roche Diagnostics GmbH, Mannheim, Germany). Patients with HPR (>46 U) were switched to prasugrel or treated with high-dose clopidogrel, and those without HPR continued treatment with 75 mg of clopidogrel.ResultsA total of 741 consecutive patients were enrolled in the study between September 2011 and August 2012, and 219 of these patients (29.5%) had HPR. Although platelet reactivity decreased after treatment adjustments in those with HPR, prasugrel provided significantly more potent platelet inhibition compared with high-dose clopidogrel (p

Full Text
View/download PDF

143. The χQCD Collaboration

Author

Alexandru, Andrei, Chen, Ying, Doi, Takumi, Dong, Shao-Jing, Draper, Terrence, Gong, Ming, Horvath, Ivan, Joo, Balint, Lee, Frank, Lewis, Randy, Li, Anyi, Liu, Keh-Fei, Mathur, Nilmani, Streuer, Thomas, Thacker, Hank, and Zhang, Jianbo

Published
2009
Full Text
View/download PDF

144. Investigation of asymmetric dimetylarginine in patients with coronary artery disease.

Author

Németh, Ádám, Ajtay, Zénó, Husznai, Róbert, Németh, Zoltán, Horváth, Iván, Szokodi, István, Szabados, Sándor, Koller, Akos, Bode-Böger, Stefanie M., and Cziráki, Attila

Subjects
PHYSIOLOGICAL effects of arginine, CORONARY disease, NITRIC oxide, NITRIC-oxide synthases, BLOOD plasma, PATIENTS
Abstract

Introduction: The concentrations of asymmetric dimethy-larginine (ADMA), an endogenous inhibitor of nitric oxide synthase are increased in patients with coronary artery disease (CAD). An elevated concentration of ADMA in the plasma and pericardial fluid (PF) is an independent predictor of worse cardiovascular events in patients undergoing coronary revascularization. We aimed to investigate the changes of pericardial and plasma ADMA levels in patients with CAD, who underwent percutaneous coronary intervention (PCI) and coronary artery bypass graft (CAbG) surgery. Patients and Methods: 64 patients who underwent PCI or CABG surgery were enrolled in this study (65.5 ± 8.2 years). 52 patients who underwent the valve replacement (VR) served as control subjects (59 ± 6.9 years). Exercise stress test was performed on a treadmill according to the Bruce protocol. ADMA levels were determined by using liquid chromatography -- tandem mass spectrometry. Furthermore L-arginine and ADMA concentrations were determined in plasma and PF of patients undergoing coronary artery bypass graft (CABG, n=28) or valve replacement (VR, n=25). Results: Patients in the CAD group had significantly elevated plasma concentrations of ADMA at rest, compared to the control group (0.59 ± 0.02 µM/l vs. 0.46 ± 0.03 µM/l; p<0.01). ADMA decreased immediately after stent implantation in the PCI group. There was no discernible increase in ADMA in the off-pump CABG group. In contrast, the levels of ADMA were significantly elevated in the group of patients who underwent cardiopulmonary bypass (CPB) (F=0.416, p<0.685 and F=14.751, p<0.001 for the off-pump and CPB groups, respectively). Similarly, a significant increase in ADMA was observed in the peripheral blood (F=30.738, p<0.001) during CPB, while during the off-pump CABG surgery, ADMA remained largely unchanged. The L-arginine/ ADMA ratio of both plasma (125.4±10.7 vs.76.7±8.7) and PF (110.4±7.2 vs. 80.8±6.04) were significantly higher in the CABG group compared to the VR group. Furthermore, there was a significant positive correlation between plasma and pericardial L-arginine levels in the CABG group. The PF ADMA was higher in the VR than CABG group. Conclusion: This clinical study highlights the importance of the investigation of both plasma and pericardial ADMA levels in patients with CAD. Changes of ADMA, and L-arginine/ADMA ratio are reliable, as well as the feasible markers of ischemia-reperfusion injury occurring in patients who underwent coronary revascularization. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

145. Signaling mechanisms mediating the positive inotropic response to apelin in the intact rat heart.

Author

Ezer, Péter, Perjés, Ábel, Skoumal, Réka, Simon, Mihály, Cziráki, Attila, Koller, Akos, Kónyi, Attila, Gábor Horváth, Iván, Ruskoaho, Heikki, and Szokodi, István

Subjects
APELIN, CARDIOTONIC agents, CARDIOVASCULAR system, CARDIAC contraction, CELLULAR signal transduction
Abstract

Background: Apelin is emerging as an important regulator of the cardiovascular system. We previously demonstrated that apelin is one of the most potent endogenous stimulators of myocardial contractility; however, the signal transduction pathways mediating this effect are still obscure. Here we studied the role of protein kinase C (PKC) and extracellular signal-regulated kinase 1/2 (ERK1/2) in the positive inotropic effect of apelin. Methods and Results: In isolated perfused rat hearts, infusion of apelin (2 nmol/L for 20 min) induced a slowly developing and sustained increase in cardiac contractility. The improvement of cardiac function was accompanied by the activation of PKC and ERK1/2. Apelin induced a transient increase in the translocation of PKC[epsilon], but not PKC[alpha], from the cytosol to the particulate fraction, and a sustained increase in the phosphorylation of ERK1/2 in the left ventricle. Pharmacological inhibition of ERK1/2 activation significantly attenuated the inotropic response to apelin. Although inhibition of PKC reduced the inotropic effect of apelin, it did not prevent the activation of ERK1/2. Conclusions: Stimulation of apelin receptors enhances myocardial contractility via parallel and independent activation of PKC[epsilon] and ERK1/2 in the intact adult rat heart. Selective activation of PKC[epsilon] and ERK1/2 signaling may represent a novel means to support cardiac function in diseased conditions. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

146. What is the limit of capability of using the bioresorbable vascular scaffold?

Author

Kittka, Bálint, Magyari, Balázs, Kónyi, Attila, Pintér, Tunde, Barth, Zoltán, Szokodi, István, Cziráki, Attila, Koller, Ákos, and Horváth, Iván G.

Subjects
DEATH, CORONARY disease, BLOOD flow, HEART, DISEASE progression
Abstract

The number of deaths caused by coronary artery disease (CAD) in the USA is 145/100.000, while in Hungary it is 332/100.000. CAD is progressive, characterized by narrowing or even blockage of the arteries causing restricted blood flow to the heart. Several risk factors can be modified by lifestyle changes, but due to other risk factors, the progression of the disease cannot be stopped despite all of the aggressive pharmacological therapies. There is expectation for brand new devices and techniques in the therapy of CAD. The first bioresorbable vascular scaffold (BVS) implantation around the world was performed by P. Serruys and his team in the Netherlands. In Hungary the first BVS was implanted in 2012. This was the second generation BVS. The BVS is a temporary scaffold indicated for improving coronary luminal diameter that will eventually resorb and potentially facilitate normalization of the vessel function in patients with ischemic heart disease due to de novo native coronary artery lesions. One of the first institutes in Hungary was the Heart Institute of the University of Pécs, which had the opportunity to apply several BVS. In our lab some of the procedures were controlled by optical coherence tomography (OCT), which ensured the perfect apposition and sizing of the stents. The treated lesion length should be less than the nominal scaffolding length, (12-28 mm) with reference vessel diameters ≥2.0 mm and ≤3.8 mm. The scaffold is contraindicated for the patients who are contraindicated to receive antiplatelet or anticoagulant therapy, who show hypersensitivity to aspirin, clopidogrel, ticlopidine, prasugrel, ticagrelor, everolimus, poly(L-lactide), poly (D,L-lactide), or platinum. In total, we have implanted 14 BVS in 7 patients so far, which is 2 scaffolds per patient on the average. We have both used the BVS with the typical indications and with off-label indications as well. We would use this poster to share our experience we have gained by applying the scaffold. As the second point, we would like to highlight the most frequent complications and the special implantation technique which is mandatory to be carried out while a bioresorbable vascular scaffold system is being implanted. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

149. Optimizing P2Y12 Receptor Inhibition in Patients With Acute Coronary Syndrome on the Basis of Platelet Function Testing: Impact of Prasugrel and High-Dose Clopidogrel.

Author

Aradi, Dániel, Tornyos, Adrienn, Pintér, Tünde, Vorobcsuk, András, Kónyi, Attila, Faluközy, József, Veress, Gábor, Magyari, Balázs, Horváth, Iván G., and Komócsi, András

Subjects
*PURINERGIC receptors, *ACUTE coronary syndrome, *PLATELET function tests, *PRASUGREL, *CLOPIDOGREL, *TREATMENT of acute coronary syndrome, *PATIENTS, *THERAPEUTICS
Abstract

Objectives: This study sought to evaluate the impact of treatment with prasugrel and high-dose clopidogrel on the basis of platelet function testing in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI). Background: The clinical impact of treatment with prasugrel in patients with ACS who have high platelet reactivity (HPR) is unknown. Methods: Patients with ACS who were pre-treated with clopidogrel and undergoing successful PCI were enrolled in a single-center, prospective registry. Platelet function was measured 12 to 36 h after PCI with the Multiplate device (Roche Diagnostics GmbH, Mannheim, Germany). Patients with HPR (>46 U) were switched to prasugrel or treated with high-dose clopidogrel, and those without HPR continued treatment with 75 mg of clopidogrel. Results: A total of 741 consecutive patients were enrolled in the study between September 2011 and August 2012, and 219 of these patients (29.5%) had HPR. Although platelet reactivity decreased after treatment adjustments in those with HPR, prasugrel provided significantly more potent platelet inhibition compared with high-dose clopidogrel (p < 0.0001). Compared with patients without HPR, the risk of all-cause death, myocardial infarction, stent thrombosis, or stroke at 1 year was significantly higher in the high-dose clopidogrel group (hazard ratio [HR]: 2.27; 95% confidence interval [CI]: 1.45 to 3.55; p < 0.0001), and patients who were switched to prasugrel had similar outcomes (HR: 0.90; 95% CI: 0.44 to 1.81; p = 0.76). Bleeding Academic Research Consortium (BARC) type 3/5 bleeding was also more frequent in patients treated with high-dose clopidogrel (HR: 2.09; 95% CI: 1.05 to 4.17; p = 0.04) than in patients switched to prasugrel (HR: 0.45; 95% CI: 0.11 to 1.91; p = 0.28). In a multivariate model, HPR with high-dose clopidogrel, but not with prasugrel, was an independent predictor of the composite ischemic endpoint (HR: 1.90; 95% CI: 1.17 to 3.08; p = 0.01). Conclusions: Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results